// App-Quantinova.ai

1503 : Imatinib (IM) and Interferon-Alpha (IFN-a) Maintenance Therapy Is Associated with Long-Term DFS in a Subset of Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Researchers

Presenter

  • Sylvia Wystub

Principal Investigators

  • A. Binckebanck

  • Dieter Hoelzer

  • Oliver G. Ottmann

  • Barbara Wassmann

  • Andreas Kabisch

  • Michael Lubbert

  • Lothar Leimer

  • Aristoteles Giagounidis

  • Winfried Gassmann

  • Patrick Brueck

  • Hubert Serve

Medical Centers

  • Praxis Fur Hamatologie Und Onkologie, Wiesbaden, Germany

  • Department of Hematology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany

  • Department of Internal Medicine II, Hematology and Oncology, Goethe University Hospital, Frankfurt, Germany

  • Robert-Bosch Krankenhaus, Stuttgart, Germany

  • Department of Hematology and Oncology, University Medical Center, Freiburg, Germany

  • Medizinische Klinik II, St. Johannes Hospital, Duisburg, Germany

  • Department of Medicine, Hematology/Oncology, Goethe University of Frankfurt, Frankfurt, Germany

  • Goethe University, Frankfurt, Germany

  • Department of Medicine, Hematology/Oncology, Goethe University of Frankfurt, Frankfurt, Germany

  • Department of Medicine, Hematology/Oncology, Goethe University of Frankfurt, Frankfurt, Germany

Locations

  • Germany

Companies

  • St. Marien-Krankenha

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Depression

  • Philadelphia chromosome–positive (Ph+) ALL

Biomarkers

  • Breakpoint Cluster Region

  • Interferon-alpha

Drug/Treatment

  • Imatinib

  • Interferon alpha

  • Interferon

  • dasatinib

  • IkT001

  • L-Tyrosine

  • IFN-lambda

Outcome

  • N/A

Study Design

  • open label

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved